Back to search

Spain· ES:99127020

INTRONA 10 MILLONES DE UI/ml SOLUCION INYECTABLE O PARA PERFUSION

A interferon alfa-2b product containing interferon alfa-2b, registered in Spain by Merck Sharp & Dohme B.V.. The same ATC class is registered in 5 of our 19 countries.

ATC L03AB05

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedINTRONA 10 MILLONES DE UI/ml SOLUCION…ATCL03AB05REGISTER NO.ES:99127020PACKS LISTED0CHECKEDSeptember 12, 2026

Where it is registered

Interferon alfa-2b is registered in 5 of 19 countries.

Countries holding a registration under ATC L03AB05 (interferon alfa-2b), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 3 of them publish a price we can compare per daily dose

Interferon alfa-2b · ATC L03AB05

5 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Netherlands
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

AEMPS CIMA (Spain)
Active substance
interferon alfa-2b
Manufacturer
Merck Sharp & Dohme B.V.
Country
Spain (ES)
ATC code
L03AB05
ATC class
Interferon alfa-2b
Defined daily dose
2 MIO, E
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

230 interactions on record for interferon alfa-2b.

Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Interferon alfa-2b · interactions on record

230 records

  • 37 severe
  • 191 moderate
  • 2 minor

Most severe, free to view

  • EltrombopagB02BX05severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/28aae7a2-a997-455f-9221-3dad1614dd6f
GET /v1/drugs/28aae7a2-a997-455f-9221-3dad1614dd6f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Diagnóstico Hospitalario",
  "estado": "{\"aut\":959551200000,\"rev\":1644998376000}",
  "nregistro": "99127020",
  "substance": "interferon alfa-2b"
}

See everything about interferon alfa-2b.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.